Biofrontera INC 8-K filings

Biofrontera's Phase 3 study of Ameluz-PDT for superficial Basal Cell Carcinoma (sBCC) shows highly significant positive results, mirroring European data.

Biofrontera Inc. has secured FDA approval to increase the maximum dosage of Ameluz topical gel from one to three tubes per treatment, allowing for more comprehensive treatment of actinic keratosis.

Biofrontera Inc. announced a 34% increase in second-quarter revenue and a significant reduction in net loss compared to the same period last year.

Biofrontera has announced the launch of its FDA-approved RhodoLED XL, a red light emitting LED lamp for photodynamic therapy.

Biofrontera Inc. stockholders approved an amendment to the 2021 Omnibus Incentive Plan, increasing the authorized shares by 3,483,010 to a total of 3,750,000.

Biofrontera Inc. received a notice from Nasdaq stating they are currently in compliance with listing rule 5550(b)(1), but may face delisting if they fail to maintain compliance in their next periodic report.

Biofrontera Inc. reported a 9% decrease in first-quarter revenue to $7.9 million, primarily due to reimbursement headwinds caused by the Change Healthcare data breach, but saw a 123% increase in BF-RhodoLED lamp placements.

Biofrontera Inc. has successfully met two key milestones related to its Series B-3 Convertible Preferred Stock warrants, triggering an $8 million funding injection.

Biofrontera Inc. has increased its authorized common stock shares from 15 million to 35 million after shareholder approval at a special meeting on April 24, 2024.

Biofrontera Inc. stockholders voted to increase the number of authorized common shares from 15 million to 35 million at a special meeting held on April 24, 2024.

Biofrontera Inc. has amended the record date for its 2024 Annual Meeting of Stockholders from April 22, 2024, to April 15, 2024.

Biofrontera Inc. has announced its 2024 Annual Meeting of Stockholders will be held on June 12, 2024, and has provided revised deadlines for stockholder proposals and director nominations.

Biofrontera Inc. reported record total revenues of $34.1 million for 2023, a 19% increase over the previous year, alongside strategic organizational and product development advancements.

Biofrontera Inc. has successfully closed an $8 million private placement with healthcare-focused investors, with a potential for an additional $8 million based on achieving certain milestones.

Biofrontera Inc. has significantly restructured its supply agreement with Biofrontera AG, reducing transfer prices and gaining control of US clinical trials, while also securing a private placement of up to $16 million.

Biofrontera Inc. reports a voluntary recall of a limited number of Ameluz product lots by its licensor due to a packaging defect, with no anticipated material financial impact on the company.

Biofrontera Inc. has received FDA confirmation that its application to increase the maximum dosage of Ameluz from one to three tubes per treatment is complete and will proceed to substantive review.

Biofrontera Inc. has amended its payment schedule with related entities and completed the exercise of all pre-funded warrants, resulting in a total of 2,572,628 outstanding shares.

Biofrontera Inc. has received a 180-day extension from Nasdaq to regain compliance with listing requirements, now due by May 20, 2024.

Biofrontera Inc. reports preliminary record revenues for 2023, reaching approximately $33.8 million to $34.3 million, a 19% increase compared to 2022.